PP_1170x120_10-25-21

Regeneron Pharmaceuticals

Regeneron announces start of REGN-COV2 phase 3 COVID-19 prevention trial

Regeneron announces start of REGN-COV2 phase 3 COVID-19 prevention trial

TARRYTOWN, N.Y. — Regeneron Pharmaceuticals announced the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron’s investigational double antibody cocktail for the treatment and prevention of COVID-19. A Phase 3 trial will evaluate REGN-COV2’s ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient (such as the patient’s housemate), and is being run

Regeneron inks manufacturing and supply agreement with BARDA and U.S. Department of Defense for REGN-COV2 anti-viral antibody cocktail

Regeneron inks manufacturing and supply agreement with BARDA and U.S. Department of Defense for REGN-COV2 anti-viral antibody cocktail

TARRYTOWN, N.Y. —  Regeneron Pharmaceuticals announced Tuesday that, as part of Operation Warp Speed, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, and the Department of Defense Joint Program Executive Office for Chemical, Biological,